Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Weightloss in Menopause

Susan Brian

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Treatment of Chronic Kidney Disease and Heart Failure Circa 2024

WCIRDC

K. R. Tuttle

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

Tirzepatide Updates

Diana Isaacs

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover